Latest news
Categories
News archive
Nanologicas delårsrapport jan-sep 2021
29 October, 2021
FINANSIELL SAMMANFATTNING Nettoomsättningen för tredje kvartalet uppgick till 2 119 TSEK (2 089) och för niomånadersperioden till 12 238 TSEK (10 064) Rörelseresultatet för kvartalet uppgick till -11 718 TSEK (-5 795) och för niomånadersperioden till -26 581 TSEK (-15 924) Resultatet efter skatt för kvartalet uppgick till -12 546 TSEK (-5 899) och för niomånadersperioden till -29 607 TSEK (-16 772) Resultat per aktie före och efter utspädning var -0,45 SEK (-0,21) för kvartalet och
Nanologica Interim Report Jan – Sep 2021
29 October, 2021
FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 2,119 (2,089) and for the nine-month period to TSEK 12,238 (10,064) The operating result for the quarter amounted to TSEK -11,718 (-5,795) and for the nine-month period to TSEK -26,581 (-15,924) Result after tax for the quarter amounted to TSEK -12,546 (-5,899) and for the nine-month period to TSEK -29,607 (-16,772) Earnings per share before and after dilution were SEK -0.45 (-0.21) for the
CEO comment third quarter 2021
29 October, 2021
FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to TSEK 2,119, most of which again is derived from our partner project with Vicore Pharma. The quarter’s increased operating loss compared to the previous year is according to plan and is mainly due to the expansion phase in which the company is currently in. To take the next step in our growth, we are now fully focused on completing large-scale production capacity, which is
Nanologica to Exhibit on BCEIA
17 September, 2021
Nanologica will exhibit on BCEIA (Beijing Conference and Exhibition an Instrumental Analysis) held in Beijing Sep 27-29. BCEIA is a world exposition on analytical science and biochemical technology that attracted more than 25,000 registered participants in 2017.
Nanologica Closes NIC-001
17 September, 2021
Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company’s resources on the continued development of the inhalation platform NLAB Spiro®. The closure of the project is a result of the company’s strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001